MedTrace Logo

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

NCT02658396 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2017-07-05

No results posted yet for this study

Summary

This research study is studying a combination of targeted therapies known as GO-203-2C and bortezomib as a possible treatment for multiple myeloma that has either progressed or not responded to treatment.

Conditions

Interventions

DRUG

GO-203-2C

DRUG

Bortezomib

Sponsors & Collaborators

Principal Investigators

  • Jacalyn Rosenblatt, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2019-05-31
Completion
2022-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02658396 on ClinicalTrials.gov